Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
9 evidence topics · 9 sources
Multidisciplinary care model across primary care, endocrinology, and hepatology (AASLD 2023)
“Optimal care of the patient with NAFLD requires a multidisciplinary approach. The majority of patients are in the primary care/endocrine setting, in which management of medical comorbidities should be optimized, with preference given to treatments for type 2 diabetes mellitus, hypertension, or obesity that likely also have beneficial effects on NAFLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The role of the gastroenterologist/hepatologist includes more comprehensive liver risk stratification, exclusion of other liver diseases, and a focus on liver-directed therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients should undergo dietary/nutritional assessment and a plan established for regular follow-up independent of gastroenterology/hepatology visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multidisciplinary management recommendation (EASL-EASD-EASO)
AGA clinical care pathway: risk stratification in primary care and hepatologist-coordinated care for high-risk patients
“As a result, FIB-4 provides a useful, inexpensive, first-line assessment of liver fibrosis for use in primary care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that these patients be managed by a multidisciplinary team closely coordinated by a hepatologist who can monitor for cirrhosis, HCC, and other cirrhosis-related complications. In these patients, we recommend aggressive lifestyle changes aimed at long-term weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA Standards of Care 2026: screening and referral of adults with type 2 diabetes or prediabetes
“Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Refer adults with type 2 diabetes or prediabetes at higher risk for significant liver fibrosis (i.e., as indicated by FIB-4, liver stiffness measurement, or ELF) to a gastroenterologist or hepatologist for further evaluation and management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-treatment monitoring and discontinuation criteria for resmetirom at 12 months (AASLD October 2024 update)
Response and futility assessment for semaglutide at 72 weeks (AASLD November 2025 update)
Treatment response definition at 1 year (updated global consensus 2026)
“The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment response at 1 year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacist-led prescription pathway for resmetirom in a US health system
“Our health system allocated a senior and experienced PharmD pharmacist (Phoebe Shackelford) to champion the resmetirom prescription pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our prescription pathway effectively dispensed resmetirom to nearly all patients who were prescribed resmetirom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in 6 patients discontinued resmetirom, primarily due to side effects. This high discontinuation rate may be mitigated by modifying our follow-up from” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote